Search Videos and More
News
Dana-Farber Research Publication 01.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Research Publication 12.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Symposium
2024 SABCS Highlights
Dana-Farber Cancer Institute Faculty highlights from the 2024 San Antonio Breast Cancer Symposium.
News
Dana-Farber Research Publication 12.1.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Symposium
2023 ASH Highlights
Review presentations and information shared by Dana-Farber physician-scientists at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego.
Symposium
2023 SABCS Highlights
Dana-Farber Cancer Institute Faculty highlights from the 2023 San Antonio Breast Cancer Symposium.
News
2023 Updates in Neuro-Oncology
Please join us on Zoom for a free symposium on the latest advances in neuro-oncology. Through lecture and discussion, Harvard Medical School faculty will consider how to apply recent clinical research advances to improve the care and outcomes of patients with brain tumors.
News
Dana-Farber Research Publication 11.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Symposium
2023 ESMO Congress Research Highlights
Learn more about lung, kidney, and neuroendocrine tumor cancer studies led by Dana-Farber presented at ESMO Congress 2023.
News
Dana-Farber Research Publication 11.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Document
Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
News
Dana-Farber Research Publication 10.15.2022
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.